Cambium Bio Limited (CMB.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.42 (+0.00%) as of
Key statistics
- Market cap
- 12.36M
- EPS (TTM)
- -0.1700
- Dividend yield
- 0.00%
- 52-week range
- 0.3400 – 0.6000
- Beta
- -0.52
- Revenue (TTM)
- 1.23M
- Profit margin
- 0.00%
- Volume
- 1.47k
About Cambium Bio Limited
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bella Vista, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.